CVS and Cardinal Health Ink 10-Year Generic-Drug Deal

CVS and Cardinal Health Ink 10-Year Generic-Drug Deal

In what will become the largest, independent generic-drug sourcing concern in the U.S., according to CVS Caremark and Cardinal Health , the two sides have signed an agreement to form an equal partnership in which each will source and negotiate favorable generic drug contracts to the benefit of both CVS and Cardinal, the health-services giants announced today.

CVS, as part of the agreement that will initially last for 10 years, will receive annual payments associated with the deal from Cardinal of $25 million. CVS said the after-tax value of the payments, in today's dollars, is equal to $435 million. The deal will require little to no capital outlay from either CVS or Cardinal, the companies said. Instead, the partnership will utilize the "sourcing and supply chain expertise" of each.

The president and CEO of CVS Caremark, Larry Merlo, said, "This partnership will enable us to maintain our leadership role in navigating the dynamic U.S. generics market." Cardinal Health Chairman and CEO George Barrett added, "This venture is an extremely compelling combination where volume and efficiency matter."

CVS Caremark and Cardinal Health also announced that they have agreed to extend their existing distribution contract by three years, to 2019. The distribution deal, which was initially scheduled to expire in 2016, was just renewed in April of this year.

The joint venture is subject to signing final documents and customary closing conditions and should be in place by July 1.

The article CVS and Cardinal Health Ink 10-Year Generic-Drug Deal originally appeared on

Fool contributor Tim Brugger and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Originally published